Search Results - "Baumgaertner, I"

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study by Bachet, J.B., Bouché, O., Taieb, J., Dubreuil, O., Garcia, M.L., Meurisse, A., Normand, C., Gornet, J.M., Artru, P., Louafi, S., Bonnetain, F., Thirot-Bidault, A., Baumgaertner, I., Coriat, R., Tougeron, D., Lecomte, T., Mary, F., Aparicio, T., Marthey, L., Taly, V., Blons, H., Vernerey, D., Laurent-Puig, P.

“…RAS mutations are currently sought for in tumor samples, which takes a median of almost 3weeks in western European countries. This creates problems in clinical…”
Get full text

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer by Mineur, L, François, E, Plassot, C, Phelip, J M, Miglianico, L, Dourthe, L M, Bonichon, N, Moreau, L, Guimbaud, R, Smith, D, Achille, E, Hervé, R, Bons, J M, Remy, S, Faroux, R, Villing, A L, Mahamat, A, Rabbia, I, Soulié, P, Baumgaertner, I, Mathé, N, Vazquez, L, Boustany, R

“…Cetuximab improves progression-free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC). Few data…”
Get full text

How to monitor outpatients undergoing active anticancer treatment? A feasibility study of the web-based tool "Onco'nect®" by Belhadj, M, Kempf, E, Lebel, A, Guillemin, A, Boussion, H, Joly, C, Baumgaertner, I, Assaf, E, Saldana, C, Rousseau, B J-C, Tournigand, C

Get full text

Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial by Sobhani, I., Itti, E., Luciani, A., Baumgaertner, I., Layese, R., André, T., Ducreux, M., Gornet, J.-M., Goujon, G., Aparicio, T., Taieb, J., Bachet, J.-B., Hemery, F., Retbi, A., Mons, M., Flicoteaux, R., Rhein, B., Baron, S., Cherrak, I., Rufat, P., Le Corvoisier, P., de’Angelis, N., Natella, P.-A., Maoulida, H., Tournigand, C., Durand Zaleski, I., Bastuji-Garin, S.

“…[18F]2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18FDG-PET/CT) has high sensitivity for detecting recurrences of colorectal…”
Get full text

2316 Efficacy and toxicity of second-line chemotherapy in patients with advanced oesophageal squamous cell carcinoma progressing after a first line of 5-fluorouracil and platinum-based therapy: An AGEO retrospective multicentric study by Auzolle, C, Dubreuil, O, Pozet, A, Coriat, R, Dhooge, M, Ducreux, M, Mons, M, Brieau, B, Baumgaertner, I, Gornet, J.M, Li évre, A, Locher, C, Mary, F, Bonnetain, F, Landi, B

Get full text

1549 Blood alcohol level in patients treated with gemcitabine and taxanes by Assaf, E, Verlinde-Carvalho, M, Daher, H, Hulin, A, Faye, E, Rousseau, B, Baumgaertner, I, Chaubet, M, Joly, C, Saldana, C, Taleb, A, Astier, A, Paul, M, Tournigand, C

Get full text

Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review by Baumgaertner, I, Ratziu, V, Vaillant, J-C, Hannoun, L, Poynard, T, André, T

“…Hepatic toxicity of chemotherapy for colorectal cancer and its complications after hepatic metastasis surgery are unclear. Studies reporting hepatic lesions…”
Get more information

Toxicité hépatique de la chimiothérapie du cancer colorectal métastatique : revue de la littérature by Baumgaertner, I., Ratziu, V., Vaillant, J.-C., Hannoun, L., Poynard, T., André, T.

“…La toxicité hépatique de la chimiothérapie du cancer colorectal (CCR) et ses complications après chirurgie des métastases hépatiques sont mal évaluées. Les…”
Get full text

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach by Boisdron-Celle, M, Capitain, O, Faroux, R, Borg, C, Metges, J.P, Galais, M.P, Kaassis, M, Bennouna, J, Bouhier-Leporrier, K, Francois, E, Baumgaertner, I, Guerin-Meyer, V, Cojocarasu, O, Roemer-Becuwe, C, Stampfli, C, Rosenfeld, L, Lecompte, T, Berger, V, Morel, A, Gamelin, E

“…Background 5-FU-based treatments can lead to early-onset severe (4 to 5%) even fatal (0.3%) toxicities in patients with dihydropyrimidine dehydrogenase (DPD)…”
Get full text

CN65How to monitor outpatients undergoing active anticancer treatment? A feasibility study of the web-based tool "Onco'nect®" by Belhadj, M, Kempf, E, Lebel, A, Guillemin, A, Boussion, H, Joly, C, Baumgaertner, I, Assaf, E, Saldana, C, Rousseau, B J-C, Tournigand, C

Get full text

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial by Karoui, Mehdi, Gallois, Claire, Piessen, Guillaume, Legoux, Jean‐Louis, Barbier, Emilie, De Chaisemartin, Cecile, Lecaille, Cedric, Bouche, Olivier, Ammarguellat, Hanifa, Brunetti, Francesco, Prudhomme, Michel, Regimbeau, Jean‐Marc, Glehen, Olivier, Lievre, Astrid, Portier, Guillaume, Hartwig, Johannes, Goujon, Gael, Romain, Benoit, Lepage, Come, Taieb, Julien, Ainseba, N., Alcaraz, L., Audemar, F., Bachet, J. B., Bardier, A., Baumgaertner, I., Luciani, A., Bège, T., Ben Abdelghani, M., Bourgeois, V., Brigand, C., Couteau, C., Champetier, C., Chauvenet, M., Debourdeau, P., Deguelte, S., Poizat, F., Sarran, A, Deplanque, G., Olivier, D., Duluc, M., Faucheron, J. L., François, Y., Freddy, M., Gasmi, M., Gornet, J. M., Gualtierotti, M., Lacaze, L., Lagasse, J. P., Lepere, C., Loriau, J., Malaurie, E., Manfredi, S., Mauvais, F., Meunier, B., Mineur, L., N’Guyen, S., Obled, S., Oden Gangloff, A., Ollier, J. C., Pelletier, A. L., Pere Verge, D., Peschaud, F., Pezet, D., Ramdani, M., Ries‐guye, P., Rougier, P., Rullier, E., Sabbagh, C., Saudemont, A., Seitz, J. F., Sobhani, I., Tessier, W., Tougeron, D.

“…Aim Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon cancer (CC) but its effect on oncological outcomes is uncertain. The aim…”
Get full text

124P - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt) by Rousseau, BJ-C, Cohen, J., Calderaro, J., Dupuy, A., Bourgoin, R., Tournigand, C., Baumgaertner, I., Ropert, S., Thirot Bidault, A., Klotz, C., Le Foll, C., Boussion, H., Diaz, L.A., Ollier, M., Pujals, A.

“…MMR Deficiency (dMMR) and edPOLE mutations (mt) are responsible for hypermutated tumoral phenotype. Immunotherapy have shown efficacy in dMMR/high mutation…”
Get full text

Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt) by Rousseau, BJ-C, Cohen, J., Calderaro, J., Dupuy, A., Bourgoin, R., Tournigand, C., Baumgaertner, I., Ropert, S., Thirot Bidault, A., Klotz, C., Le Foll, C., Boussion, H., Diaz, L.A., Ollier, M., Pujals, A.

Get full text

124PClinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt) by Rousseau, BJ-C, Cohen, J, Calderaro, J, Dupuy, A, Bourgoin, R, Tournigand, C, Baumgaertner, I, Ropert, S, Thirot Bidault, A, Klotz, C, Le Foll, C, Boussion, H, Diaz, L A, Ollier, M, Pujals, A

“…Abstract Background MMR Deficiency (dMMR) and edPOLE mutations (mt) are responsible for hypermutated tumoral phenotype. Immunotherapy have shown efficacy in…”
Get full text

Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas by Goislard de Monsabert, Camille, Touchefeu, Yann, Guiu, Boris, Campillo-Gimenez, Boris, Farges, Olivier, Tougeron, David, Baumgaertner, Isabelle, Ayav, Ahmet, Beuzit, Luc, Pracht, Marc, Lièvre, Astrid, Le Sourd, Samuel, Boudjema, Karim, Rolland, Yan, Garin, Etienne, Boucher, Eveline, Edeline, Julien

“…In the Yttrium-90 Microspheres in Cholangiocarcinoma (MISPHEC) single-arm phase 2 trial, concomitant chemotherapy and selective internal radiotherapy (SIRT)…”
Get full text

Comparison of l and dl forms of folinic acid in Gercor C96.1 trial (A phase III trial comparing bimonthly LV5FU2 to monthly high-dose 5FU-leucovorin in patients with Dukes’ B2 and C colon cancer) by Quinaux, E. M., Baumgaertner, I., Khalil, A., Louvet, C., Buyse, M. E., de Gramont, A., André, T.

“…Abstract only e15004 In C96.1 study (André T et al; J Clin Oncol. 2007 20;25:3732–8), patients were randomized to either monthly 5FU-LV hd (dl LV 200 mg/m 2 or…”
Get full text

Vaskulitis interdisziplinär by Thalhammer, C., Baumgartner, I.

Get full text

Sekundärprävention bei der peripheren Verschlusskrankheit der unteren Extremitäten by Böhner, H., Kröger, K., Baumgartner, I.

Get full text

Angiologie: Aspirin® bei peripherer arterieller Verschlusskrankheit … ein Irrtum? by Baumgartner, I

Get full text

Breeding for fire blight resistance in apple by Kellerhals, M, Franck, L, Baumgartner, I.O, Patocchi, A, Frey, J.E

“…Different sources of fire blight (Erwinia amylovora) resistance are available for breeding fire blight resistant apples. The development of molecular markers…”
Get full text